Draft legislation would establish uniform, electronic drug tracking system

A bipartisan draft bill would create a uniform, national traceability system that tracks drugs from their manufacturing source through their final destination on drugstore shelves.

The discussion draft, released by Sens. Lamar Alexander (R-Tenn.), Michael Bennet (D-Colo.), Richard Burr (R-N.C.) and Tom Harkin (D-Iowa) of the Senate Health, Education, Labor and Pensions Committee, would amend the federal Food, Drug and Cosmetic Act to replace state product tracing laws with a nationwide electronic, interoperable unit level product tracing system.

Under the bill, every entity in the drug supply chain—including manufacturers, repackagers, wholesale distributors, third-party logistic providers and dispensers—would be required to input transaction information and ownership change information. No player in the chain could accept drugs lacking sufficient transaction information.

Licensing requirements for wholesale distributors and third-party logistic providers also are tightened in the bill. The FDA likewise would manage a publicly available online database of wholesale distributors. “This empowers both consumers and members of the pharmaceutical distribution supply chain to identify appropriately licensed wholesalers,” according to the senators’ April 22 statement on the draft.

"Over the past few years, we’ve had a record number of recalls and reports of tainted or ineffective drugs reaching our hospitals and drugstore shelves,” Sen. Bennet said in the statement. “In fact, right now, we know more from a barcode on a gallon of milk than from a barcode on a bottle of pills, which could mean the difference between life and death. This draft bill would put steps in place to prevent and reduce those problems and help ensure our drug supply is safe.”

The senators are seeking comment on the draft until April 26.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup